NCT06566807: Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma |
|
|
| Recruiting | 2 | 51 | RoW | Orelabrutinib, obinutuzumab | Huai'an First People's Hospital | Marginal Zone Lymphoma | 08/26 | 08/28 | | |
| Recruiting | N/A | 30 | RoW | zanubrutinib 160 mg BID orally, rituximab: 375 mg/m2 intravenously on day 7, methotrexate: 3-3.5 g/m2 intravenously on day 1, temozolomide 100 mg on days 1-5 | Huai'an First People's Hospital, Affiliated Hospital of Nantong University, The First People's Hospital of Changzhou, The Affiliated Hospital of Xuzhou Medical University, Northern Jiangsu People's Hospital | Primary Central Nervous System Lymphoma | 04/26 | 04/26 | | |
NCT06328179: Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. |
|
|
| Recruiting | N/A | 34 | RoW | Venetoclax 100 mg d1，200 mg d2，400 mg d3-14；, Homoharringtoine, HHT 2 mg/m2，qd，d1-7, Etoposide 0.1 g，qd，d1-5, Cytarabine 100 mg/m2，qd，d1-7 | Huai'an First People's Hospital, Zhenjiang First People's Hospital, The First People's Hospital of Changzhou, The Affiliated Hospital of Xuzhou Medical University | Acute Myeloid Leukemia | 12/27 | 12/27 | | |
